Your session is about to expire
Zemplar vs Sensipar
Introduction
For patients struggling with secondary hyperparathyroidism, a condition related to chronic kidney disease (CKD), certain medications like Zemplar and Sensipar can help manage symptoms and regulate levels of necessary compounds in the body. Both drugs target different aspects of this complex hormonal system but have proven effective in managing the impacts of this disorder. Zemplar is classified as a vitamin D analog, which helps control parathyroid hormone (PTH) levels by increasing calcium absorption from the gut and reducing PTH release from the parathyroids. On the other hand, Sensipar is a calcimimetic agent that mimics calcium's action on tissues, specifically lowering PTH secretion through its effect on calcium-sensing receptors located on parathyroid cells.
Zemplar vs Sensipar Side By Side
| Attribute | Zemplar | Sensipar |
|---|---|---|
| Brand Name | Zemplar | Sensipar |
| Contraindications | Should not be taken with CYP3A4 inhibitors such as ketoconazole. Not to be used if calcium levels are too high. | Not to be used if PTH levels are already low. Should not be taken with CYP3A4 inhibitors such as ketoconazole. |
| Cost | $170 for 30 capsules of 1 mcg | $930 for 30 tablets of 30 mg |
| Generic Name | Paricalcitol | Cinacalcet |
| Most Serious Side Effect | High calcium levels - nausea, vomiting, constipation, increased thirst or urination, muscle weakness, bone pain | Signs of low calcium levels such as muscle spasms or contractions and tingling sensations around mouth area. |
| Severe Drug Interactions | Interactions with CYP3A4 inhibitors | Interactions with CYP3A4 inhibitors |
| Typical Dose | 1–8 mcg/day | 30 mg/day, up to 180 mg/day |
What is Zemplar?
Paricalcitol (the generic name for Zemplar) is a drug used to prevent and treat high parathyroid hormone levels. It was first approved by the FDA in 1998. Zemplar works by mimicking vitamin D, necessary for the absorption of calcium from the stomach and functioning of calcium in the body. By doing so, it helps reduce parathyroid hormone levels which can be elevated in people with chronic kidney disease.
Cinacalcet (the generic name for Sensipar), on other hand, directly lowers parathyroid hormone levels by increasing sensitivity of calcium-sensing receptor (CaSR) to extracellular calcium. This results in decreased PTH secretion which is beneficial for patients suffering from hyperparathyroidism secondary to kidney diseases or cancer treatments.
While both drugs are effective at managing high parathyroid hormone levels, they work differently and have different side effects profiles. For instance, Zemplar may cause an overabundance of vitamin D leading to abnormal heart rhythms while Sensipar can lower blood pressure drastically if not monitored closely.
What conditions is Zemplar approved to treat?
Zemplar is approved for the treatment of various forms of hyperparathyroidism:
- Secondary hyperparathyroidism in people with chronic kidney disease on dialysis
- Hyperparathyroidism related to stage 3 or 4 chronic kidney disease
Sensipar, on the other hand, is used to treat:
- Secondary hyperparathyroidism in adults with chronic kidney disease who are on dialysis
- High levels of calcium in people with parathyroid cancer
- Severe high levels of calcium in people with primary and certain types of secondary hyperparathyroidism who can't be treated through surgery.
How does Zemplar help with these illnesses?
Zemplar works to manage secondary hyperparathyroidism in patients with chronic kidney disease by regulating the amount of active vitamin D available. It does this by acting as a synthetic form of active Vitamin D, directly increasing its levels and thereby helping control parathyroid hormone (PTH) secretion from the parathyroid glands. PTH is a hormone that plays an important role in maintaining calcium and phosphate balance, amongst other things. Overproduction of PTH can lead to serious bone diseases and cardiovascular problems. Therefore, by mimicking active vitamin D, Zemplar can limit the negative effects of high PTH levels.
On the other hand, Sensipar helps to treat secondary hyperparathyroidism not through vitamin D pathways but via direct action on the parathyroid gland itself. It acts as a calcimimetic agent which stimulates calcium-sensing receptors on these glands tricking them into believing there's more calcium present than there actually is; thus reducing PTH production and release.
Both drugs aim at controlling excessive secretion of Parathyroid Hormone (PTH), yet they act through different mechanisms making their side effect profiles distinct.
What is Sensipar?
Sensipar, also known as cinacalcet, is a calcimimetic agent that works by mimicking the action of calcium on tissues. It increases the sensitivity of the calcium-sensing receptor (CaSR) to activation by extracellular calcium in the body. Sensipar was approved by FDA in 2004 and it is used for treating secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma. Unlike Zemplar (paricalcitol), which is a vitamin D analog used to prevent and treat high levels of parathyroid hormone, Sensipar does not have vitamin D activity or its associated side effects such as an increased risk of hypercalcemia. This makes it suitable for patients who do not respond well to typical Vitamin D analogs like Zemplar. However, common side effects of Sensipar include nausea, vomiting and diarrhea but are usually mild to moderate.
What conditions is Sensipar approved to treat?
Sensipar is approved by the Food and Drug Administration for the treatment of:
- Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis
- Hypercalcemia in adult patients with parathyroid carcinoma
- Severe hypercalcemia in adult patients with primary HPT who would be at increased risk of complications from surgery.
How does Sensipar help with these illnesses?
Calcimimetics are a class of drugs that help regulate calcium levels in the body and play key roles in numerous processes, impacting bone strength, muscle contraction and nerve function. Low levels of calcium can lead to serious conditions like osteoporosis or hypocalcemia. Sensipar works by mimicking calcium's action on parathyroid hormone (PTH) production, thereby reducing PTH concentrations which consequently decreases serum calcium and phosphorus levels. This makes it particularly useful for patients with chronic kidney disease who often have elevated blood phosphate or PTH levels. In contrast to Zemplar, Sensipar does not run the risk of vitamin D toxicity since it doesn't rely on increasing active Vitamin D levels for its effectiveness. It is sometimes prescribed when a patient cannot tolerate the side effects associated with vitamin D analogs such as Zemplar or if an alternative method to control PTH concentration is required.
How effective are both Zemplar and Sensipar?
Both paricalcitol (Zemplar) and cinacalcet (Sensipar) have proven effective in managing secondary hyperparathyroidism, a common complication of advanced chronic kidney disease, and were initially approved by the FDA within three years of each other. They work via different mechanisms: paricalcitol is a vitamin D analog that suppresses PTH synthesis and secretion directly at the source in the parathyroid gland, while cinacalcet increases sensitivity of calcium-sensing receptor on the chief cells of the parathyroid gland to extracellular calcium.
A 2003 study showed both drugs' effectiveness in reducing levels of PTH; however, side-effect profiles differed between patients treated with Zemplar versus Sensipar. Patients receiving cinacalcet experienced gastrointestinal symptoms more frequently than those receiving paricalcitol.
A meta-analysis review conducted in 2017 reported that Zemplar has significant efficacy from first week onward for treating secondary hyperparathyroidism due to chronic kidney disease stage 5D. It has been widely prescribed around world because its safety profile fares favorably against most active vitamin D sterols available today. The optimal dose varies depending on patient's baseline iPTH level but generally lies within range of 1 mcg/day -15 mcg/week intravenously or orally.
In contrast to this comprehensive data supporting use of Zemplar as one-line treatment option for secondary hyperparathyroidism, evidence concerning Sensipar is less robust when used alone. However, it shines as an adjunctive therapy alongside Vitamin D agents like Zemplar particularly for refractory cases unable to achieve desired outcome with monotherapy approach despite optimal dosing strategy being adhered to.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Zemplar typically prescribed?
Oral dosages of Zemplar range from 1–8 mcg/day, but research suggests that a starting dose of 1 mcg/day is effective in managing secondary hyperparathyroidism for most people. In contrast, the dosage regimen for Sensipar begins at 30 mg once daily and may be increased every two to four weeks up to a maximum dosage of 180 mg/day depending on response. For both medications, careful monitoring by healthcare professionals is necessary due to their potential side effects and interactions with other drugs.
At what dose is Sensipar typically prescribed?
Sensipar therapy is typically initiated at a dosage of 30 mg/day. This dose can be increased to 60 or 120 mg/day, divided into two doses, spaced 12 hours apart. The maximum daily dose is usually around 180 mg/day split into three doses of 60 mg and taken every eight hours, which may be tested if there is no therapeutic response to treatment at the lower dosages after several weeks.
What are the most common side effects for Zemplar?
Common side effects of Zemplar (Paricalcitol) can include:
- Nausea or vomiting
- Swelling in your hands, ankles, or feet
- Weakness, dizziness and fatigue
- Increased thirst
- Irregular heartbeat
- Constipation
On the other hand, Sensipar (Cinacalcet) could cause different side effects like:
- Nausea and vomiting
- Diarrhea
- Loss of appetite
- Muscle pain or cramps
- Dizziness
- Fatigue and weakness
Are there any potential serious side effects for Zemplar?
When using Zemplar, be aware of the following potential side effects and contact your healthcare provider if you experience any:
- Signs of an allergic reaction such as hives; difficulty breathing; swelling in your face, lips, tongue or throat
- Unusual weakness or tired feeling
- A light-headed sensation like you might pass out
- Fast or irregular heartbeats
- Shortness of breath
- Swelling around your eyes
- High calcium levels - nausea, vomiting, constipation, increased thirst or urination, muscle weakness, bone pain
On the other hand with Sensipar:
- Symptoms indicating low calcium levels such as muscle spasms or contractions and tingling sensations around mouth area.
- Signs suggestive of an allergic response: hives; difficult breathing; face/throat edema.
- Indications for upper stomach problems may appear: severe pain spreading to back along with nausea/vomiting.
In both cases make sure to seek immediate medical attention.
What are the most common side effects for Sensipar?
Sensipar, a medication often used to treat secondary hyperparathyroidism and hypercalcemia, can have an array of side effects. These may include:
- Nausea or vomiting
- Lack of appetite
- Dizziness or lightheadedness
- Fatigue or weakness
- Muscle spasms or joint pain
- Headaches
- Frequent urination There could be a risk for hypotension (low blood pressure) leading to blurred vision. Some patients may experience mental changes such as confusion, anxiety, and occasional insomnia. Sweating and rash are less common but possible side effects. Weight loss can occur due to the lack of appetite and nausea caused by Sensipar.
Are there any potential serious side effects for Sensipar?
Sensipar, although beneficial for many patients with chronic kidney disease and secondary hyperparathyroidism, can occasionally lead to severe side effects. Such symptoms may include:
- Signs of an allergic reaction, such as itching or hives; swelling in your face or hands; swelling or tingling in your mouth or throat; chest tightness; trouble breathing
- Unusual bleeding, bruising, or weakness
- Fast heartbeat
- Muscle pain, cramps, spasms
- Numbness and tingling around the mouth
- Severe nausea, vomiting
- Shortness of breath
If you experience any of these serious side effects while on Sensipar therapy, it is crucial that you contact a healthcare professional immediately. Remember: monitoring by a medical provider is key when taking this medication for optimal outcomes and safety.
Contraindications for Zemplar and Sensipar?
Both Zemplar and Sensipar, like many other medications used for managing chronic kidney disease, may cause side effects in some patients. If you notice an increase in symptoms such as nausea, vomiting or a decrease in appetite while taking either drug, be sure to contact your healthcare provider immediately.
Neither Zemplar nor Sensipar should be taken if you are using or have recently stopped using certain types of drugs known as CYP3A4 inhibitors (such as ketoconazole). Always inform your physician about all the medications you're currently taking; these specific drugs may interact with Zemplar and require a period of time to clear from the system before starting therapy with this medication.
It's also crucial to mention that both medicines can affect calcium levels within the body. Patients need to monitor their blood calcium levels regularly when on these treatments because excessive changes can lead to serious health problems. Lastly, it is imperative not to use Sensipar if parathyroid hormone (PTH) levels are already low.
How much do Zemplar and Sensipar cost?
For the brand name versions of these drugs:
- The price for 30 capsules of Zemplar (1 mcg) averages around $170, which works out to approximately $5.60/day.
- The price for 30 tablets of Sensipar (30 mg) is about $930, working out to a hefty $31/day.
Thus, if you are taking standard dosages of each medication, brand-name Zemplar comes at a significantly lower cost per day compared to Sensipar. However, it's important to note that cost should not be the primary factor in determining which drug is right for your health needs.
Currently there are no generic versions available for either Zemplar (paricalcitol) or Sensipar (cinacalcet), so costs remain relatively high compared with many other medications. Please consult your healthcare provider and consider both medical efficacy and personal budget when making treatment decisions.
Popularity of Zemplar and Sensipar
Paricalcitol, available under the brand name Zemplar, is a vitamin D analog used for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease. In 2020, approximately 150,000 prescriptions were filled in the U.S., making it an essential medication in nephrology.
On the other hand, Cinacalcet sold as Sensipar also treats secondary hyperparathyroidism but works differently; it mimics calcium to decrease parathyroid hormone levels. Approximately 200,000 Sensipar prescriptions were filled in America during 2020. While both are indicated for similar purposes within nephrology practice and dialysis centers across America, their mechanisms of action differ substantially.
It's important to note that while these drugs are often used complementarily in clinical practice for managing advanced stages of chronic kidney disease complications like renal osteodystrophy or high phosphate levels seen typically among dialysis patients they do not substitute one another directly due to different pharmacological actions.
Conclusion
Both Zemplar (paricalcitol) and Sensipar (cinacalcet) have a proven track record in managing secondary hyperparathyroidism, especially in patients with chronic kidney disease. They are supported by multiple clinical trials indicating their effectiveness over placebo treatments. Although these drugs can be used together when needed, this should be under careful supervision by a healthcare provider due to potential interactions between them.
Zemplar and Sensipar have different mechanisms of action - Zemplar is an active form of Vitamin D that helps regulate the levels of parathyroid hormone (PTH), calcium, and phosphorus in the body. On the other hand, Sensipar works directly on the parathyroid gland to decrease PTH production.
While both medications come as generic options which may result in significant cost savings for patients paying out-of-pocket, it's important to note that they might require some time before their effects become noticeable.
The side effect profiles for both drugs are generally similar; common side effects include nausea or vomiting. However, each drug has unique adverse events: Zemplar may cause high levels of calcium or vitamin D while Sensipar could lead to low calcium levels. As such, close monitoring is required when starting treatment with either medication. Should any severe symptoms occur such as bone pain or irregular heartbeats patients should immediately seek medical help.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Block, G. A., Martin, K. J., de Francisco, A. L. M., Turner, S. A., Avram, M. M., Suranyi, M. G., … Goodman, W. G. (2004, April 8). Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal of Medicine. Massachusetts Medical Society.http://doi.org/10.1056/nejmoa031633
- Goodman, W. G. (2004, September). Calcimimetic agents for the treatment of secondary hyperparathyroidism. Seminars in Nephrology. Elsevier BV.http://doi.org/10.1016/j.semnephrol.2004.06.006
- Poon, G. (2005, April). Cinacalcet Hydrochloride (Sensipar). Baylor University Medical Center Proceedings. Informa UK Limited.http://doi.org/10.1080/08998280.2005.11928062
- Coburn, J. W., & Maung, H. M. (2000, March). Calcimimetic agents and the calcium-sensing receptor. Current Opinion in Nephrology and Hypertension. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/00041552-200003000-00005
- Ketteler, M., Martin, K. J., Wolf, M., Amdahl, M., Cozzolino, M., Goldsmith, D., … Khan, S. (2012, March 2). Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation. Oxford University Press (OUP).http://doi.org/10.1093/ndt/gfs018
- Cheng, S., & Coyne, D. (2006, March). Paricalcitol in the treatment of secondary hyperparathyroidism. Expert Review of Endocrinology & Metabolism. Informa UK Limited.http://doi.org/10.1586/17446651.1.2.159
- de Francisco, A. L. (2005, March). Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opinion on Pharmacotherapy. Informa UK Limited.http://doi.org/10.1517/14656566.6.3.441